Abbott (ABT)'s Volt™ PFA System, the latest generation of cardiac ablation technology, is designed for people battling heart rhythm disorders such as atrial fibrillation (AFib) Pulsed field ablation – ...
Abbott Laboratories said it is set to roll out its Volt PFA System in the U.S., following federal approval, and continue expanding the cardiology tool throughout Europe. The U.S. Food and Drug ...
On December 22, Abbott Laboratories (NYSE:ABT) said the US Food and Drug Administration has approved the company’s Volt™ PFA System to treat patients with atrial fibrillation, or AFib. The company ...
Add Yahoo as a preferred source to see more of our stories on Google. Abbott's Volt pulsed field ablation catheter. Abbott said Monday that it has received Food and Drug Administration approval for ...
Two years after the U.S. FDA approved the first pulsed field ablation system, Abbott Laboratories finally got the regulatory nod for its Volt PFA system. Abbott follows Medtronic plc, Boston ...
Positive 12-month results from the VOLT-AF IDE Study presented at the AF Symposium and simultaneously published in JACC: Clinical Electrophysiology, reinforce the Volt™ Pulsed Field Ablation (PFA) ...
Abbott Laboratories ABT recently received FDA approval for its Volt PFA System to treat patients battling atrial fibrillation (AFib). The company is expected to begin commercial PFA cases in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results